Swedish Orphan Biovitrum AB Reports Q1 2025 Results

Swedish Orphan Biovitrum AB (SOBI), a leading biopharmaceutical company listed on the Swedish Stock Exchange, has announced its financial results for the first quarter of 2025. The company, which specializes in developing therapies for haemophilia, inflammation, genetic, rare, and debilitating diseases, reported a total revenue increase of 3% to SEK 6,465 million, up from SEK 6,256 million in the previous year, when adjusted for constant exchange rates (CER).

Haematology Revenue Growth

The haematology segment saw a significant revenue increase of 13% at CER, reaching SEK 4,632 million. This growth was primarily driven by the successful launch of Altuvoct, which generated SEK 455 million in sales. Additionally, strong sales of Doptelet contributed SEK 1,129 million, and Aspaveli/Empaveli added SEK 333 million. However, these gains were somewhat offset by a decrease in sales of Vonjo, which fell to SEK 306 million from SEK 320 million.

Immunology Segment Challenges

In contrast, the immunology segment experienced a 21% decrease in revenue at CER, dropping to SEK 1,526 million. This decline was largely due to low sales of Synagis, which fell to SEK 21 million from SEK 520 million, and a reduction in Beyfortus royalties, which decreased to SEK 189 million from SEK 318 million. Despite these challenges, the segment saw strong sales of Gamifant, contributing SEK 582 million, and Kineret, which added SEK 735 million.

Market Position and Outlook

With a market capitalization of SEK 98.26 billion and a price-to-earnings ratio of 24.6, SOBI continues to be a significant player in the biotechnology sector. The company’s ability to deliver growth in its haematology portfolio while navigating challenges in its immunology segment highlights its strategic focus and resilience.

For more detailed information, stakeholders and interested parties can visit SOBI’s official website at www.sobi.com .